Unnamed: 0,title,date,stock,sentiment
190127.0,"The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant",2020-05-29 07:22:00-04:00,BSTC,positive
190128.0,BioSpecifics Names Joseph Truitt Permanent CEO,2020-05-11 08:17:00-04:00,BSTC,neutral
190129.0,"BioSpecifics Technologies Q1 EPS $0.610 Up From $0.600 YoY, Sales $9.669M Up From $8.129M YoY",2020-05-11 08:12:00-04:00,BSTC,neutral
190130.0,BioSpecifics Reports CEO J. Kevin Buchi Leaving Co.; Names Joseph Truitt Interim CEO,2020-04-09 08:09:00-04:00,BSTC,neutral
190131.0,"The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test",2020-03-24 08:20:00-04:00,BSTC,negative
190132.0,BioSpecifics Technologies Q4 EPS $1 Up From $0.84 YoY,2020-03-16 16:02:00-04:00,BSTC,neutral
190133.0,"BioSpecifics Technologies Q3 EPS $0.85 Up From $0.69 YoY, Sales $9.442M Up From $8.168M YoY",2019-11-08 08:20:00-05:00,BSTC,neutral
190134.0,"The Daily Biotech Pulse: Biogen Alzheimer's Program Back On Track, Novartis Reports Strong Quarter, Takeda In-Licenses Autoimmune Disorder Drug",2019-10-22 07:51:00-04:00,BSTC,positive
190135.0,"The Daily Biotech Pulse: FDA Panel Backs Shionogi's Antibiotic, Hepion Surges On Data Publication, Innate Pharma IPO",2019-10-17 07:39:00-04:00,BSTC,negative
190136.0,"The Daily Biotech Pulse: Reata Leaps On Positive Readout, Takeda Divests, FDA Nod For Akorn, J&J Earnings",2019-10-15 07:50:00-04:00,BSTC,positive
190137.0,Stocks That Hit 52-Week Lows On Tuesday,2019-10-08 12:02:00-04:00,BSTC,negative
190138.0,Stocks That Hit 52-Week Lows On Thursday,2019-10-03 13:03:00-04:00,BSTC,negative
190139.0,Stocks That Hit 52-Week Lows On Tuesday,2019-10-01 14:35:00-04:00,BSTC,negative
190140.0,"BioSpecifics Technologies Q2 EPS $0.88 Up From $0.66 YoY, Sales $8.853M Up From $7.096M YoY",2019-08-09 16:11:00-04:00,BSTC,neutral
190141.0,BioSpecifics Reports $4M Buyback,2019-05-23 08:29:00-04:00,BSTC,neutral
190142.0,"BioSpecifics Technologies Q1 EPS $0.61 Misses $0.62 Estimate, Sales $8.1M Inline",2019-05-10 08:03:00-04:00,BSTC,negative
190143.0,"BioSpecifics Technologies Q4 EPS $0.85 Beats $0.82 Estimate, Sales $9.9M Beat $9.89M Estimate",2019-04-02 08:02:00-04:00,BSTC,neutral
190144.0,"The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results",2019-02-05 07:47:00-05:00,BSTC,positive
190145.0,"The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug",2019-01-18 07:49:00-05:00,BSTC,neutral
190146.0,"BioSpecifics Technologies Q3 EPS $0.69 Beats $0.55 Estimate, Sales $8.17M Beat $7.23M Estimate",2018-11-09 08:04:00-05:00,BSTC,neutral
190147.0,"Stocks Which Set New 52-Week High Yesterday, Wed., Nov. 7, 2018",2018-11-08 10:52:00-05:00,BSTC,neutral
190148.0,BioSpecifics Reports Phase 1 Study of CCH For Treatment Of Uterine Fibroids Met Primary Endpoint Of Safety And Tolerability With No Observed Clinically Significant Adverse Reactions,2018-10-31 16:48:00-04:00,BSTC,neutral
190149.0,"Stocks Which Set New 52-Week High Yesterday, October 23rd",2018-10-24 09:15:00-04:00,BSTC,neutral
190150.0,"Stocks Which Set New 52-Week High Yesterday, September 13th",2018-09-14 09:26:00-04:00,BSTC,neutral
190151.0,"Stocks Which Set New 52-Week High Yesterday, September 11th",2018-09-12 12:17:00-04:00,BSTC,neutral
190152.0,"The Daily Biotech Pulse: Foamix Jumps on Data, Positive Results for Galapagos-Gilead's Rheumatoid Arthritis Drug, Bausch Health Trims Debt",2018-09-12 08:26:00-04:00,BSTC,positive
190153.0,"The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet",2018-09-11 08:25:00-04:00,BSTC,negative
190154.0,"Stocks Which Set New 52-Week High Friday, September 7th",2018-09-10 16:36:00-04:00,BSTC,neutral
190155.0,"Stocks Which Set New 52-Week High Yesterday, September 4th",2018-09-05 10:22:00-04:00,BSTC,neutral
190156.0,"Stocks Which Set New 52-Week High Friday, August 31",2018-09-04 10:29:00-04:00,BSTC,neutral
190157.0,"Stocks Which Set New 52-Week High Yesterday, August 14th",2018-08-15 12:29:00-04:00,BSTC,neutral
190158.0,"BioSpecifics Technologies Q2 EPS $0.60 Beats $0.49 Estimate, Sales $7.096M Beat $7.07M Estimate",2018-08-09 08:02:00-04:00,BSTC,neutral
190159.0,BioSpecifics Technologies Q1 EPS $0.55 Misses $0.59 Estimate,2018-05-09 08:25:00-04:00,BSTC,negative
190160.0,"BioSpecifics Technologies Reports Q4 EPS $0.36 vs $0.39 Est., Sales $6.7M vs $6.8M Est.",2018-03-14 08:06:00-04:00,BSTC,neutral
190161.0,"H.C. Wainwright Maintains Buy on BioSpecifics Technologies, Lowers Price Target to $65.00",2017-11-13 11:11:00-05:00,BSTC,negative
190162.0,"BioSpecifics Technologies Reports Q3 EPS $0.37 vs $0.36 Est., Sales $6.5M vs $6.6M Est.",2017-11-10 08:03:00-05:00,BSTC,neutral
190163.0,"BioSpecifics Tech Reports Q2 EPS $0.36 vs $0.39 Est., Sales $6.5M vs $6.95M Est.",2017-08-09 16:59:00-04:00,BSTC,neutral
190164.0,"BioSpecifics Technologies Corp. Reports Q1 EPS $0.47 vs $0.40 Est., Sales $7.7M vs $6.8M Est.",2017-05-10 16:39:00-04:00,BSTC,neutral
190165.0,"BioSpecifics Technologies Corp. Reports Q4 EPS $0.41 vs. $0.38 Est., Sales $6.62M vs. $6.76M Est.",2017-03-15 08:02:00-04:00,BSTC,neutral
190166.0,"BioSpecifics Announces Phase 2b Data For XIAFLEX, Showed Significant Improvement In Primary Endpoint",2016-11-17 16:27:00-05:00,BSTC,positive
190167.0,Stifel Healthcare Conference Today,2016-11-15 10:53:00-05:00,BSTC,neutral
190168.0,"BioSpecifics Reports Q3 EPS $0.43 vs. Est. $0.41, Rev. $6.9M vs. Est. $7M",2016-11-09 17:08:00-05:00,BSTC,neutral
190169.0,"18 Stocks Which Rallied Four Days, Then Sold Off Yesterday",2016-09-30 10:59:00-04:00,BSTC,neutral
190170.0,Mid-Morning Market Update: Markets Open Higher; Lennar Tops Q3 Expectations,2016-09-20 10:15:00-04:00,BSTC,positive
190171.0,25 Stocks Which Rallied Three Days,2016-09-16 08:04:00-04:00,BSTC,neutral
190172.0,"BioSpecifics Reports Q2 EPS $0.35, Inline, Sales $6.2M vs $6.25M Est.",2016-08-09 17:01:00-04:00,BSTC,neutral
190173.0,BioSpecifics Technologies Reveals Positive Top-Line Results From Stage 2 Study Of CCH For Treatment of Human Lipoma,2016-06-13 09:49:00-04:00,BSTC,positive
190174.0,BioSpecifics Technologies Reveals Positive Top-Line Results from Stage 2 Study Of CCH For Treatment of Human Lipoma,2016-06-13 08:55:00-04:00,BSTC,positive
190175.0,BioSpecifics Technologies Corp. Reports Positive Top-Line Results from Phase 2 Trial Meets Primary And Secondary Endpoint,2016-06-13 07:33:00-04:00,BSTC,positive
190176.0,BioSpecifics Technologies Corp. Announces Publication of Encouraging Data for Uterine Fibroid Treatment with CCH in American Journal of Obstetrics & Gynecology,2016-05-31 07:33:00-04:00,BSTC,positive
190177.0,BioSpecifics Technologies Reports Positive Uterine Fibroid Treatment Data With CCH In American Journal Of Obstetrics & Gynecology,2016-05-31 07:32:00-04:00,BSTC,positive
190178.0,BioSpecifics Reports Q1 EPS $0.39 vs $0.37 Est.,2016-05-10 07:35:00-04:00,BSTC,neutral
190179.0,"BioSpecifics Technologies Q4 EPS $0.36, No Est",2016-03-14 07:02:00-04:00,BSTC,negative
190180.0,Benzinga's Top Initiations,2016-03-08 09:32:00-05:00,BSTC,positive
190181.0,"Rodman & Renshaw Initiates Coverage on BioSpecifics Technologies at Buy, Announces $60.00 PT",2016-03-08 07:07:00-05:00,BSTC,neutral
190182.0,"BioSpecifics Technologies Reports Q3 EPS $0.39, Sales $6.29M, no estimates",2015-11-09 07:31:00-05:00,BSTC,negative
190183.0,BioSpecifics Technologies Corp. Announces First Commercial Sale of XIAFLEX® for the Treatment of Dupuytren's Contracture in Japan,2015-09-21 08:02:00-04:00,BSTC,neutral
190184.0,Mid-Day Market Update: Joy Global Drops On Earnings Miss; Methode Electronics Shares Spike Higher,2015-09-03 13:01:00-04:00,BSTC,positive
190185.0,BioSpecifics Technologies Corp. Reports Formal Pricing of XIAFLEX for the Treatment of Dupuytren's Contracture in Japan,2015-08-31 08:44:00-04:00,BSTC,neutral
190186.0,Mid-Day Market Update: National Penn Bancshares Surges On Acquisition News; Vera Bradley Shares Slide,2015-08-18 12:47:00-04:00,BSTC,positive
190187.0,BioSpecifics Board Reports $2.5M Buyback,2015-08-17 16:52:00-04:00,BSTC,neutral
190188.0,"BioSpecifics Tech Reports Q2 EPS $0.24, Sales $4.71M, no estimates",2015-08-10 16:25:00-04:00,BSTC,negative
190189.0,BioSpecifics Announces Approval of XIAFLEX® in Japan for the Treatment of Dupuytren's Contracture,2015-07-20 08:05:00-04:00,BSTC,positive
190190.0,BioSpecifics Technologies Corp. Announces New Positive Data On XIAFLEX,2014-11-21 08:33:00-05:00,BSTC,positive
190191.0,"Events for the Week of Nov. 17-21, 2014",2014-11-17 13:13:00-05:00,BSTC,neutral
190192.0,BioSpecifics Technologies Corp. Announces FDA Approval of sBLA for XIAFLEX ,2014-10-21 08:17:00-04:00,BSTC,positive
190193.0,BioSpecifics Announces Positive Phase 2 Data for CCH,2014-08-21 17:42:00-04:00,BSTC,positive
190194.0,BioSpecifics Technologies Corp Reports Q2 EPS of $0.08 vs $0.12 Est; Revenue of $2.65M vs $2.91M Est,2014-08-11 16:22:00-04:00,BSTC,neutral
190195.0,BioSpecifics Announces Initiation of Phase 2 Study of CCH,2014-08-08 08:30:00-04:00,BSTC,neutral
190196.0,"BioSpecifics Technologies Corp. Announces Appointment Of Max Link, Ph.D. To Board ",2014-08-05 08:32:00-04:00,BSTC,neutral
190197.0,Amended 13D Filing from Stonepine Capital on Biospecifics Technologies Shows Reduced Stake from 6.33% as of Feb. 25th to 4.9%,2014-06-30 14:00:00-04:00,BSTC,neutral
190198.0,BioSpecifics Technologies Corp. to Be Added to Russell 3000® Index,2014-06-27 08:31:00-04:00,BSTC,neutral
190199.0,BioSpecifics Technologies Corp Reports Q1 EPS of $0.11 vs $0.14 Est; Revenue of $2.76M vs $3.46M Est,2014-05-08 08:27:00-04:00,BSTC,neutral
190200.0,BioSpecifics Technologies Corp Reports Q4 EPS of $0.25 vs $0.17 Est; Revenue of $4.07M vs $3.38M Est,2014-03-06 08:06:00-05:00,BSTC,neutral
190201.0,BioSpecifics Technologies Initiates Phase 2b Trial of CCH for Treatment of Frozen Shoulder Syndrome ,2013-12-13 08:44:00-05:00,BSTC,neutral
190202.0,BioSpecifics Technologies Corp Reports Q3 EPS of $0.17 vs $0.10 Est; Revenue of $3.15M vs $2.97M Est,2013-11-12 08:09:00-05:00,BSTC,neutral
190203.0,"BioSpecifics Technologies Announces Partnership between Auxilium, Swedish Orphan Biovitrum AB for XIAPEX in Eurasia and Africa ",2013-07-16 19:48:00-04:00,BSTC,neutral
190204.0,"Earnings Scheduled For May 10, 2013",2013-05-10 04:51:00-04:00,BSTC,neutral
190205.0,Aegis Capital Reiterates Buy Rating on BioSpecifics Technologies Ahead of Conference Call,2013-03-11 12:56:00-04:00,BSTC,neutral
190206.0,BioSpecifics Technologies Reports Q3 EPS $0.07 vs $0.17 Est,2012-11-08 16:18:00-05:00,BSTC,neutral
190207.0,BioSpecifics Technologies Corp. Announces Presentation of Additional Phase III Data from XIAFLEX® Clinical Trials for Peyronie's Disease at SMSNA/ISSM Joint Annual Meeting ,2012-08-27 17:59:00-04:00,BSTC,neutral
190208.0,"Aegis Capital Initiates Coverage on BioSpecifics Technologies at Buy, Announces PT of $50",2012-08-16 07:30:00-04:00,BSTC,neutral
190209.0,BioSpecifics Technologies Corp. Announces Initiation of XIAFLEX Phase II Trial for Human Lipomas ,2012-06-26 16:35:00-04:00,BSTC,neutral
190210.0,BioSpecifics Technologies Corp. Announces Initiation of XIAFLEX Phase II Trial for Human Lipomas ,2012-06-26 16:33:00-04:00,BSTC,neutral
190212.0,"UPDATE: Stifel Nicolaus Initiates Buy, $29 Target on BioSpecifics Technologies",2012-03-15 12:03:00-04:00,BSTC,neutral
190213.0,"Stifel Nicolaus Maintains BioSpecifics Technologies at Buy, Announces PT of $29",2012-03-15 08:03:00-04:00,BSTC,neutral
190214.0,"BioSpecifics Announces Partnership Between Auxilium and Actelion for XIAFLEX in Canada, Australia, Brazil and Mexico ",2012-02-23 16:26:00-05:00,BSTC,neutral
190215.0,BioSpecifics Technologies Corp Announces Appointment of George Gould to Board of Directors  ,2011-12-09 08:03:00-05:00,BSTC,neutral
190216.0,Auxilium Pharmaceuticals and BioSpecifics Technologies Announce Plans to Develop Additional Indications using XIAFLEX,2011-08-31 20:39:00-04:00,BSTC,neutral
190217.0,BioSpecifics Technologies Announces Board Authorization of up to $2 Million Share Repurchase Program,2011-06-20 07:01:00-04:00,BSTC,positive
190218.0,"Hapoalim Securities Terminates Healthcare Coverage Including Bristol-Myers, Eli Lilly, Merck and Pfizer",2011-06-01 12:13:00-04:00,BSTC,positive
190219.0,Hapoalim Cutting Ocverage On Multitude Of Names,2011-06-01 11:48:00-04:00,BSTC,negative
190220.0,BioSpecifics Announces Positive XIAPEX® Data Presented at XVI Annual Federation of European Societies for Surgery of the Hand Congress,2011-06-01 07:03:00-04:00,BSTC,positive
190221.0,BioSpecifics Technologies Corp. Provides Update on XIAPEX Launch Progress in EU ,2011-05-20 16:04:00-04:00,BSTC,positive
190222.0,BioSpecifics Technologies Corp. Provides Update on XIAPEX Launch Progress in EU; Available Now in 7 Countries  ,2011-05-20 16:01:00-04:00,BSTC,positive
190223.0,Hapoalim Securities Reports on BioSpecifics (BSTC),2011-05-11 08:37:00-04:00,BSTC,positive
190224.0,BioSpecifics Technologies Corp. Announces Launch of XIAPEX by Pfizer for Treatment of Dupuytren's Contracture in Europe ,2011-04-11 16:08:00-04:00,BSTC,neutral
190225.0,Global Hunter Reiterates Buy on BioSpecifics Technologies Corp. (BSTC),2011-03-23 08:16:00-04:00,BSTC,neutral
190226.0,BioSpecifics Technologies Corp. Reports Q4 EPS of $0.02 vs. $(0.04),2011-03-11 07:10:00-05:00,BSTC,neutral
190227.0,BioSpecifics Technologies Posts Q3 Loss,2010-11-08 06:49:00-05:00,BSTC,negative
190228.0,BioSpecifics Technologies Corp. Announces Initiation of Global Phase 3 Trial of XIAFLEX,2010-10-12 14:31:00-04:00,BSTC,neutral
